Clinical Trial Update: Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors [Phase 3]

View source ↗

Summary

Phase 3 clinical study investigating DC-CIK cell therapy as a post-remission treatment for malignant tumors is ongoing, with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm

Drugs mentioned

• DC-CIK cells (dendritic cell-cytokine-induced killer cells)

Snippet

Sponsor: Li Yu | Conditions: Malignant Neoplasm | Phase 3 | Status: UNKNOWN